Garamycin ophthalmic solution enters market
NEW YORK — Fera Pharmaceuticals has launched an ocular bacterial infections treatment.
The company announced the launch of Garamycin (gentamicin sulfate) ophthalmic solution USP, designed to treat such infections as conjunctivitis, keratitis and blepharitis.
Last year, Fera broadened its Garamycin product offerings with the launch of preservative-free Garamycin ophthalmic ointment.
Study: Insulin lispro premixed insulin analogs may be more cost-effective Type 2 diabetes treatment
SAN DIEGO — An insulin product made by Eli Lilly appears likely to be more cost-effective than long-acting insulin analog, according to a study presented Friday at the American Diabetes Association’s 71st Scientific Sessions in San Diego.
The company conducted a study comparing the cost-effectiveness of LAIA, insulin lispro mix 75/25 and insulin lispro mix 50/50 in patients with Type 2 diabetes. Lilly sells insulin lispro under the brand name Humalog.
Analysis of the study found that for patients who do not experience frequent hypoglycemia, insulin lispro premixed insulin analogs are likely to be more cost-effective than LAIA in the long-term treatment of the disease.
FDA accepts regulatory filing for Prochieve
LIVINGSTON, N.J. — The Food and Drug Administration has accepted a regulatory approval application for a drug designed to prevent premature birth in pregnant women.
Columbia Labs and Watson Pharmaceuticals announced Monday that the FDA would review their application for Prochieve (progesterone gel) for the reduction of risk of preterm birth in women with short uterine cervical length in the third trimester of pregnancy.
“We are pleased to achieve this important regulatory milestone and look forward to working with the FDA as they review the data package for the Prochieve new drug application,” Columbia president and CEO Frank Condella said.
Under a collaborative agreement between Watson and Columbia, Watson will make a $5 million milestone payment to Columbia.